Free tool
Rare disease stocks
We cover 11 companies grouped under the Rare disease theme. The median market value in the group is $61.56M. Across the group, the median move over the past trading day is +0.74%. Price change over the past year runs from −33.9% to +340.7% across the middle 80 percent of the group, with a median of +46.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
11 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +12.68% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +182.02% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.17B | Mid cap | +340.71% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| PAR.AX | Paradigm Biopharmaceuticals Limited | $96.60M | Micro cap | −22.41% |
| 0IIM.L | Esperion Therapeutics, Inc. | $61.56M | Micro cap | +46.64% |
| NSRX | Nasus Pharma Ltd. | $48.01M | Micro cap | −48.69% |
| 4884.T | Kringle Pharma, Inc. | $22.99M | Micro cap | −7.41% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8687.69% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −33.91% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +205.34% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.